Gink­go inks $144M deal with Mer­ck to en­gi­neer en­zymes to im­prove in­gre­di­ent man­u­fac­tur­ing

While Mer­ck has not been averse to part­ner­ing with small­er com­pa­nies and the odd start­up, its lat­est part­ner­ship sees it link­ing arms with Gink­go Bioworks to help boost ac­tive phar­ma­ceu­ti­cal in­gre­di­ent pro­duc­tion through the use of en­zymes.

The part­ner­ship will have Gink­go de­vel­op a strain of bio­cat­a­lysts that can be used in chem­i­cal syn­the­sis for the pro­duc­tion of APIs. Gink­go can earn up­front R&D fees and mile­stone pay­ments, as well as com­mer­cial pay­ments which have the po­ten­tial to rake in up to $144 mil­lion for the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER